GV20 Therapeutics

GV20 Therapeutics

  • Founded: 2016
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: Solid Tumors
  • Drug types: ONC, IMM
  • Lead product: XBH25
  • Product link: https://gv20tx.com/pipeline
  • Funding: ?? B Oct 2021
  • Investors: Coatue Management, IDG Capital, 3W Investment, Watson Capital, Linear Capital



job board

Short description:

Antibody Therapeutics

Drug notes:

XBH101 RD cancers; XBH102 RD cancers; 6 add'l partnered programs RD cancer, autoimmune

Long description:

GV20 Therapeutics is leveraging artificial intelligence to develop better cancer therapeutics. Using their unique STEAD (Simultaneous Target Evaluation and Antibody Discovery) platform that integrates computation and experimentation to unlock the power of the human immune system, GV20 is discovering novel therapeutic targets and antibodies. Following discovery, targets are prioritized with functional genomics and big data. GV20’s lead candidate, GV20-0251, is a first-in-class antibody against a novel immune checkpoint, IGSF8, in clinical development as a therapy for solid tumors.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com